Adipose-derived stromal cell secretome reduces TNFα-induced hypertrophy and catabolic markers in primary human articular chondrocytes

Stefania Niada, Chiara Giannasi, Marta Gomarasca, Deborah Stanco, Sara Casati, Anna Teresa Brini

Research output: Contribution to journalArticle

Abstract

Recent clinical trials show the efficacy of Adipose-derived Stromal Cells (ASCs) in contrasting the osteoarthritis scenario. Since it is quite accepted that ASCs act predominantly through a paracrine mechanism, their secretome may represent a valid therapeutic substitute. The aim of this study was to investigate the effects of ASC conditioned medium (ASC-CM) on TNFα-stimulated human primary articular chondrocytes (CHs). CHs were treated with 10 ng/ml TNFα and/or ASC-CM (1:5 recipient:donor cell ratio). ASC-CM treatment blunted TNFα-induced hypertrophy, reducing the levels of Osteocalcin (−37%), Collagen X (−18%) and MMP-13 activity (−61%). In addition, it decreased MMP-3 activity by 59%. We showed that the reduction of MMP activity correlates to the abundance of TIMPs (Tissue Inhibitors of MMPs) in ASC secretome (with TIMP-1 exceeding 200 ng/ml and TIMP-2/3 in the ng/ml range) rather than to a direct down-modulation of the expression and/or release of these proteases. In addition, ASC secretome contains high levels of other cartilage protecting factors, i.e. OPG and DKK-1. ASC-CM comprises cartilage-protecting factors and exerts anti-hypertrophic and anti-catabolic effects on TNFα-stimulated CHs in vitro. Our results support a future use of this cell-derived but cell-free product as a therapeutic approach in the management of osteoarthritis.

Original languageEnglish
Article number101463
JournalStem Cell Research
Volume38
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Stromal Cells
Chondrocytes
Hypertrophy
Joints
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Osteoarthritis
Cartilage
Osteocalcin
Conditioned Culture Medium
Peptide Hydrolases
Collagen
Clinical Trials
Therapeutics

Keywords

  • Adipose-derived stromal cells
  • Chondrocytes
  • Hypertrophy
  • MMPs
  • Secretome
  • TIMPs

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Adipose-derived stromal cell secretome reduces TNFα-induced hypertrophy and catabolic markers in primary human articular chondrocytes. / Niada, Stefania; Giannasi, Chiara; Gomarasca, Marta; Stanco, Deborah; Casati, Sara; Brini, Anna Teresa.

In: Stem Cell Research, Vol. 38, 101463, 01.07.2019.

Research output: Contribution to journalArticle

@article{1dcc20b207c34eb3a1b4e9ded3ca5e91,
title = "Adipose-derived stromal cell secretome reduces TNFα-induced hypertrophy and catabolic markers in primary human articular chondrocytes",
abstract = "Recent clinical trials show the efficacy of Adipose-derived Stromal Cells (ASCs) in contrasting the osteoarthritis scenario. Since it is quite accepted that ASCs act predominantly through a paracrine mechanism, their secretome may represent a valid therapeutic substitute. The aim of this study was to investigate the effects of ASC conditioned medium (ASC-CM) on TNFα-stimulated human primary articular chondrocytes (CHs). CHs were treated with 10 ng/ml TNFα and/or ASC-CM (1:5 recipient:donor cell ratio). ASC-CM treatment blunted TNFα-induced hypertrophy, reducing the levels of Osteocalcin (−37{\%}), Collagen X (−18{\%}) and MMP-13 activity (−61{\%}). In addition, it decreased MMP-3 activity by 59{\%}. We showed that the reduction of MMP activity correlates to the abundance of TIMPs (Tissue Inhibitors of MMPs) in ASC secretome (with TIMP-1 exceeding 200 ng/ml and TIMP-2/3 in the ng/ml range) rather than to a direct down-modulation of the expression and/or release of these proteases. In addition, ASC secretome contains high levels of other cartilage protecting factors, i.e. OPG and DKK-1. ASC-CM comprises cartilage-protecting factors and exerts anti-hypertrophic and anti-catabolic effects on TNFα-stimulated CHs in vitro. Our results support a future use of this cell-derived but cell-free product as a therapeutic approach in the management of osteoarthritis.",
keywords = "Adipose-derived stromal cells, Chondrocytes, Hypertrophy, MMPs, Secretome, TIMPs",
author = "Stefania Niada and Chiara Giannasi and Marta Gomarasca and Deborah Stanco and Sara Casati and Brini, {Anna Teresa}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.scr.2019.101463",
language = "English",
volume = "38",
journal = "Stem Cell Research",
issn = "1873-5061",
publisher = "Elsevier",

}

TY - JOUR

T1 - Adipose-derived stromal cell secretome reduces TNFα-induced hypertrophy and catabolic markers in primary human articular chondrocytes

AU - Niada, Stefania

AU - Giannasi, Chiara

AU - Gomarasca, Marta

AU - Stanco, Deborah

AU - Casati, Sara

AU - Brini, Anna Teresa

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Recent clinical trials show the efficacy of Adipose-derived Stromal Cells (ASCs) in contrasting the osteoarthritis scenario. Since it is quite accepted that ASCs act predominantly through a paracrine mechanism, their secretome may represent a valid therapeutic substitute. The aim of this study was to investigate the effects of ASC conditioned medium (ASC-CM) on TNFα-stimulated human primary articular chondrocytes (CHs). CHs were treated with 10 ng/ml TNFα and/or ASC-CM (1:5 recipient:donor cell ratio). ASC-CM treatment blunted TNFα-induced hypertrophy, reducing the levels of Osteocalcin (−37%), Collagen X (−18%) and MMP-13 activity (−61%). In addition, it decreased MMP-3 activity by 59%. We showed that the reduction of MMP activity correlates to the abundance of TIMPs (Tissue Inhibitors of MMPs) in ASC secretome (with TIMP-1 exceeding 200 ng/ml and TIMP-2/3 in the ng/ml range) rather than to a direct down-modulation of the expression and/or release of these proteases. In addition, ASC secretome contains high levels of other cartilage protecting factors, i.e. OPG and DKK-1. ASC-CM comprises cartilage-protecting factors and exerts anti-hypertrophic and anti-catabolic effects on TNFα-stimulated CHs in vitro. Our results support a future use of this cell-derived but cell-free product as a therapeutic approach in the management of osteoarthritis.

AB - Recent clinical trials show the efficacy of Adipose-derived Stromal Cells (ASCs) in contrasting the osteoarthritis scenario. Since it is quite accepted that ASCs act predominantly through a paracrine mechanism, their secretome may represent a valid therapeutic substitute. The aim of this study was to investigate the effects of ASC conditioned medium (ASC-CM) on TNFα-stimulated human primary articular chondrocytes (CHs). CHs were treated with 10 ng/ml TNFα and/or ASC-CM (1:5 recipient:donor cell ratio). ASC-CM treatment blunted TNFα-induced hypertrophy, reducing the levels of Osteocalcin (−37%), Collagen X (−18%) and MMP-13 activity (−61%). In addition, it decreased MMP-3 activity by 59%. We showed that the reduction of MMP activity correlates to the abundance of TIMPs (Tissue Inhibitors of MMPs) in ASC secretome (with TIMP-1 exceeding 200 ng/ml and TIMP-2/3 in the ng/ml range) rather than to a direct down-modulation of the expression and/or release of these proteases. In addition, ASC secretome contains high levels of other cartilage protecting factors, i.e. OPG and DKK-1. ASC-CM comprises cartilage-protecting factors and exerts anti-hypertrophic and anti-catabolic effects on TNFα-stimulated CHs in vitro. Our results support a future use of this cell-derived but cell-free product as a therapeutic approach in the management of osteoarthritis.

KW - Adipose-derived stromal cells

KW - Chondrocytes

KW - Hypertrophy

KW - MMPs

KW - Secretome

KW - TIMPs

UR - http://www.scopus.com/inward/record.url?scp=85065740387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065740387&partnerID=8YFLogxK

U2 - 10.1016/j.scr.2019.101463

DO - 10.1016/j.scr.2019.101463

M3 - Article

C2 - 31108390

AN - SCOPUS:85065740387

VL - 38

JO - Stem Cell Research

JF - Stem Cell Research

SN - 1873-5061

M1 - 101463

ER -